Nureca Ltd Upgraded to Hold by MarketsMOJO on Improving Technicals and Financials

Technical Trends Shift to Bullish Momentum

The primary catalyst behind the upgrade is the marked improvement in Nureca’s technical profile. The technical grade has shifted from mildly bullish to bullish, signalling stronger market momentum. Key technical indicators support this positive outlook: the Moving Average Convergence Divergence (MACD) is bullish on both weekly and monthly charts, while Bollinger Bands also indicate bullish trends over these timeframes. Daily moving averages have turned bullish, reinforcing short-term momentum.

Other momentum indicators such as the Know Sure Thing (KST) oscillator show a weekly bullish stance and a mildly bullish monthly trend. The On-Balance Volume (OBV) metric, which tracks buying and selling pressure, is mildly bullish on both weekly and monthly scales, suggesting accumulation by investors. However, the Dow Theory presents a mixed picture with a mildly bearish weekly signal but a mildly bullish monthly trend, indicating some short-term caution remains.

These technical improvements have coincided with a 5.00% gain in the stock price on the day of the upgrade, closing at ₹310.95, up from the previous close of ₹296.15. The stock’s 52-week range remains wide, with a high of ₹447.00 and a low of ₹198.00, reflecting significant volatility over the past year.

Financial Trend: Positive Quarterly Performance Amid Long-Term Challenges

Financially, Nureca has demonstrated encouraging signs in the recent quarter Q3 FY25-26, which contributed to the rating upgrade. The company reported net sales of ₹39.64 crores, marking a 5.03% growth compared to previous quarters. This quarter also saw the highest Profit Before Tax excluding other income (PBT less OI) at ₹2.47 crores and the highest Profit After Tax (PAT) at ₹3.73 crores. Notably, Nureca has delivered positive results for four consecutive quarters, signalling operational stability and improving earnings quality.

Despite these short-term gains, the company’s long-term fundamentals remain weak. Operating profits have declined at a compounded annual growth rate (CAGR) of -143.07% over the past five years, indicating persistent challenges in sustaining profitability. The average Return on Equity (ROE) stands at a modest 5.62%, reflecting limited efficiency in generating shareholder returns. Additionally, the company’s EBITDA remains negative, underscoring ongoing operational risks.

Over the last year, the stock has underperformed significantly, delivering a negative return of -20.10% compared to the Sensex’s positive 8.47% gain. Over three years, the underperformance is even more pronounced, with Nureca’s stock returning -21.9% against the Sensex’s 39.07%. This persistent lag highlights the company’s struggle to keep pace with broader market and sectoral growth.

Valuation and Market Positioning

Nureca’s current valuation is considered risky relative to its historical averages. The stock trades at a price of ₹310.95, which is below its 52-week high but well above the 52-week low, indicating some recovery from previous lows. The company’s Price/Earnings to Growth (PEG) ratio is 0.3, suggesting undervaluation relative to its earnings growth potential, which has surged by 246.8% over the past year despite the stock’s negative price return.

However, the stock’s market capitalisation grade remains low at 4, reflecting its small size and limited liquidity compared to larger peers in the healthcare services sector. Promoters hold the majority stake, which can be a positive factor for stability but also concentrates control.

Quality Assessment: Mixed Signals

The overall quality grade for Nureca remains cautious. While recent quarterly results and technical indicators have improved, the company’s long-term financial health and profitability metrics are concerning. The low ROE and negative EBITDA highlight structural weaknesses, and the company’s inability to generate consistent operating profit growth over five years raises questions about its competitive positioning and operational efficiency.

Investors should weigh these quality concerns against the recent positive momentum and improved technical outlook. The upgrade to Hold reflects this balanced view, recognising the potential for recovery while acknowledging ongoing risks.

Comparative Performance and Market Context

When benchmarked against the Sensex, Nureca’s stock has shown mixed returns. In the short term, the stock has outperformed the benchmark, with a 9.95% return over the past week and 13.57% over the last month, compared to the Sensex’s marginal declines of -0.01% and -1.31% respectively. Year-to-date, Nureca has posted a slight gain of 1.07%, while the Sensex is down by 1.94%.

However, the longer-term picture is less favourable. Over one year, the stock has declined by 20.10%, significantly underperforming the Sensex’s 8.47% gain. The three-year performance gap is even wider, with Nureca down 21.9% versus the Sensex’s 39.07% rise. This persistent underperformance underscores the challenges the company faces in regaining investor confidence and market share.

Investors should consider these relative returns alongside the company’s improving technical signals and recent financial results when evaluating the stock’s medium-term prospects.

Outlook and Investment Considerations

The upgrade to a Hold rating reflects a cautious optimism about Nureca’s near-term trajectory. The improved technical indicators suggest that the stock may be entering a phase of positive momentum, supported by steady quarterly financial performance. However, the company’s weak long-term fundamentals, negative EBITDA, and underwhelming profitability metrics temper enthusiasm.

Investors are advised to monitor upcoming quarterly results closely, particularly for sustained improvements in operating profit and cash flow generation. Additionally, tracking the stock’s technical momentum and relative performance against sector peers will be crucial in assessing whether the Hold rating can be further upgraded or if risks warrant a downgrade.

Given the company’s small market capitalisation and volatile price history, Nureca remains a speculative holding best suited for investors with a higher risk tolerance and a focus on technical trading signals combined with fundamental turnaround potential.

Summary of Rating Change

On 17 January 2026, Nureca Ltd’s investment grade was upgraded from Sell to Hold, driven primarily by:

• Technical Grade: Upgraded from mildly bullish to bullish, supported by MACD, Bollinger Bands, moving averages, and OBV indicators.


• Financial Trend: Positive quarterly growth with highest net sales and profits in recent quarters, despite weak long-term operating profit CAGR.


• Valuation: Risky but showing undervaluation via PEG ratio of 0.3, with stock price recovering from lows.


• Quality: Mixed signals with low ROE and negative EBITDA, offset by recent operational improvements.

This balanced reassessment has led to a more neutral stance, reflecting both the potential for recovery and the need for caution given structural challenges.

About Nureca Ltd

Nureca Ltd operates within the healthcare services sector, specifically in medical equipment, supplies, and accessories. The company is promoter-controlled and has a market cap grade of 4, indicating a relatively small market capitalisation. Its recent financial and technical developments have attracted renewed investor attention, though it continues to face significant headwinds in profitability and long-term growth.

Investor Takeaway

For investors, the Hold rating suggests a wait-and-watch approach. The stock’s recent technical strength and quarterly earnings improvements offer some upside potential, but the company’s fundamental weaknesses and historical underperformance warrant prudence. Those considering exposure to Nureca should balance the technical momentum with the inherent risks and monitor developments closely.

Disclaimer: This analysis is based on data available as of 19 January 2026 and reflects the views of MarketsMOJO analysts. Investors should conduct their own due diligence before making investment decisions.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →